// App-Quantinova.ai

e21691 : Evaluating the appropriateness of granulocyte colony-stimulating factor (G-CSF) use in patients (pts) receiving myelosuppressive chemotherapy by febrile neutropenia (FN) risk level.

Researchers

Presenter

  • Hassam Baig

Principal Investigators

  • Zandra Karina Klippel

  • Melissa A. Pirolli

  • Barbara Somlo

  • Melissa Eisen

  • Scott Stryker

  • Spiros Tzivelekis

  • Phuong Khanh H. Morrow

Medical Centers

  • IMS HEALTH, Lost Angeles, CA

  • Amgen Inc, Thousand Oaks, CA

  • IMS Health, Los Angeles, CA

  • Amgen Inc, South San Francisco, CA

Locations

  • United States

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Human immunodeficiency virus infection

  • Neutropenia

  • Lung Cancer

  • Solid malignancies

Biomarkers

  • Granulocyte colony-stimulating factor

Drug/Treatment

  • Filgrastim

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved